Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Indian stock markets open in the red
Fri, 21 Nov 09:30 am

The major Asian stock markets have opened the day on a mixed note with markets in Japan (down 0.5%) and Malaysia (down 0.5%) leading the losses. However, stock markets in Singapore (up 0.7%) and China (up 0.6%) were trading in the green. The Indian share markets have opened the day on a weak note. Barring capital goods and software, all sectoral indices have opened in the green with the stocks in the banking and healthcare sector leading the gains.

The Sensex today is down by around 16 points (0.1%), while the NSE-Nifty is down by about 1 point (0.01%). The mid cap and small cap stocks have opened in the green with BSE Mid Cap index and BSE Small Cap index up by around 0.2% and 0.4% respectively. The rupee is currently trading at Rs 61.85 to the US dollar.

Software stocks have opened the day on a mixed note with HCL Infosys and Info edge Ltd leading the gains. However, Infosys Ltd and Wipro Ltd were leading the losses. As per a leading financial daily, Tech Mahindra Ltd has acquired Virginia based Lightbridge Communications Corporation (LCC) for an enterprise value of approximately US$ 240 m. It is noteworthy that LCC is one-of-the world's largest independent global providers of network engineering services provider with more than 5000 employees in over fifty countries. The company's annual revenue stands at nearly US$ 400 m. The deal has been funded via internal accruals and the acquisition is likely to be completed by fourth quarter of FY15.

Indian Pharma stocks have opened mixed with Panacea Biotech Ltd and Cipla Ltd leading the gains. However, Ranbaxy Laboratories Ltd and Orchid Chemicals Ltd were leading the losses. As per a leading financial daily, Cipla Ltd has announced an agreement with Serum Institute of India (SII) for distribution of paediatric vaccines in Europe. As per the agreement, SII will develop and manufacture paediatric vaccines and Cipla will seek European Medicines Agency approval. Cipla will also market the products in Europe. The arrangement thus will allow Cipla to enter into the vaccines segment. It is noteworthy that in the past six months, Cipla has strengthened its presence in Europe and launched respiratory products such as Salmeterol/Fluticasone in Germany, Sweden, Czech Republic, Slovakia and Croatia. In July, it had signed an exclusive partnership with BioQuiddity regarding regional anaesthetic applications for post surgical pain management. As per Cipla's new strategy, the company is entering into various partnership deals to establish its front end presence in various markets

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian stock markets open in the red". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.